IGF-1 (Mecasermin)

Mecasermin (recombinant human IGF-1) has several established and investigational clinical applications, with the strongest evidence supporting its use in growth disorders and emerging research in neurological conditions.

Primary Growth Hormone Insensitivity Syndrome (GHIS)

The most established clinical application for mecasermin is treating severe primary IGF-1 deficiency, particularly in patients with growth hormone insensitivity syndrome. Real-world data from the IGFD Registry demonstrates that patients treated with recombinant IGF-1 can achieve meaningful improvements in near-adult height outcomes. Clinical characteristics studies show treatment efficacy in patients with primary severe IGF-1 deficiency, though specific height gains and response rates require further detailed analysis from the registry data.

Safety Considerations

A significant clinical concern with mecasermin therapy is hypoglycemia risk. Data from the European IGFD Registry identifies frequency and predictive factors for hypoglycemia in patients receiving recombinant IGF-1 treatment. This adverse effect requires careful monitoring and patient selection, particularly important given the pediatric population typically receiving this therapy.

Investigational Neurological Applications

Several clinical trials have explored mecasermin's potential in neurological conditions:

Rett Syndrome: A completed Phase 2 trial (NCT01777542) investigated recombinant IGF-1 for Rett syndrome treatment. A systematic review examined mecasermin's efficacy in this condition, though trofinetide has emerged as a more established treatment option for Rett syndrome.

Phelan-McDermid Syndrome: A completed Phase 2 trial (NCT01525901) evaluated mecasermin in 22q13 deletion syndrome, representing research into rare genetic neurodevelopmental disorders.

Autism Spectrum Disorders: Research suggests IGF-1 may have potential as both a diagnostic biomarker and treatment target for autism spectrum disorders, though this remains investigational.

Other Investigational Uses

Clinical trials have explored mecasermin in several other conditions:

• Cardiovascular applications: A completed Phase 1/2 trial examined IGF-1's safety and efficacy in heart attack patients
• Retinopathy of prematurity: Cochrane systematic review evidence exists for IGF-1 in preventing or treating this condition in premature infants
• Bronchopulmonary dysplasia: An ongoing Phase 2 trial is recruiting extremely premature infants for BPD prevention

Biomarker Applications

Beyond therapeutic use, IGF-1 serves as a clinical biomarker in certain conditions. In hemophilic arthropathy, IGF-1 levels correlate with clinical and ultrasound scores alongside other biomarkers, potentially informing disease monitoring strategies.

Clinical Note: The evidence base varies significantly across these applications. While growth hormone insensitivity syndrome represents established clinical use with registry data, many neurological and other applications remain investigational with limited clinical trial evidence. Patients should consult with appropriate specialists regarding specific treatment decisions.